These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29376753)

  • 21. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Je Y; Kaymakcalan MD; Sonpavde G; Choueiri TK
    Br J Cancer; 2015 Jan; 112(2):296-305. PubMed ID: 25349964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.
    Sonpavde G; Je Y; Schutz F; Galsky MD; Paluri R; Rosenberg JE; Bellmunt J; Choueiri TK
    Crit Rev Oncol Hematol; 2013 Jul; 87(1):80-9. PubMed ID: 23317774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
    Ranpura V; Hapani S; Chuang J; Wu S
    Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
    J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
    Herrmann J
    Curr Oncol Rep; 2016 Jun; 18(6):33. PubMed ID: 27099141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
    Hall PS; Harshman LC; Srinivas S; Witteles RM
    JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
    Das A; Mahapatra S; Bandyopadhyay D; Samanta S; Chakraborty S; Philpotts LL; Jahangir E; Roy B
    Crit Rev Oncol Hematol; 2021 Jan; 157():103186. PubMed ID: 33309571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Je Y; Schutz FA; Choueiri TK
    Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular Toxic Effects of Targeted Cancer Therapies.
    Moslehi JJ
    N Engl J Med; 2016 Oct; 375(15):1457-1467. PubMed ID: 27732808
    [No Abstract]   [Full Text] [Related]  

  • 31. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.
    Lenihan DJ; Kowey PR
    Oncologist; 2013; 18(8):900-8. PubMed ID: 23918069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1063-73. PubMed ID: 24927771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
    Schutz FA; Je Y; Choueiri TK
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.
    Abdel-Qadir H; Ethier JL; Lee DS; Thavendiranathan P; Amir E
    Cancer Treat Rev; 2017 Feb; 53():120-127. PubMed ID: 28104567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
    Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials.
    Li J; Gu J
    Eur J Clin Pharmacol; 2017 Oct; 73(10):1209-1217. PubMed ID: 28710508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors.
    Sayegh N; Yirerong J; Agarwal N; Addison D; Fradley M; Cortes J; Weintraub NL; Sayed N; Raval G; Guha A
    Curr Cardiol Rep; 2023 Apr; 25(4):269-280. PubMed ID: 36795308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials.
    Zhang W; Feng LJ; Teng F; Li YH; Zhang X; Ran YG
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):311-320. PubMed ID: 32105149
    [No Abstract]   [Full Text] [Related]  

  • 39. Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
    Qi WX; Tang LN; He AN; Yao Y; Shen Z
    Respir Med; 2013 Aug; 107(8):1280-3. PubMed ID: 23810268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials.
    Ghatalia P; Je Y; Mouallem NE; Nguyen PL; Trinh QD; Sonpavde G; Choueiri TK
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):257-76. PubMed ID: 25523486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.